Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
967results about How to "Increased proliferation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antibodies to human programmed death receptor PD-1
ActiveUS8354509B2Increased activationIncreased proliferationSugar derivativesAntibody ingredientsProgrammed deathReceptor for activated C kinase 1
Antibodies which block the binding of human Programmed Death Receptor 1 (hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.
Owner:MERCK SHARP & DOHME BV
PD-1 binding proteins
ActiveUS8168757B2Regulating T cell responsesImprove immunityAntibody mimetics/scaffoldsAntibody ingredientsHost immunitySignalling pathways
The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.
Owner:MERCK SHARP & DOHME LLC
Method for expansion of stem cells
InactiveUS20060182724A1Increase oxygen contentAvoid clotsBiocideCosmetic preparationsCell culture mediaCell growth
A method of increasing the growth of stem cells by mixing the stem cells with a growth medium that has been conditioned by an incubation with placental tissue. The method increases the expansion of the stem cell population.
Owner:RIORDAN NEIL H
Selectively negotiated ridershare system comprising riders, drivers, and vehicles
InactiveUS20090248587A1Increase widespread proliferationFlexible waysPayment architectureFuzzy logic based systemsRankingSelection criterion
A ridesharing system and method involving selected negotiated participation of riders and ride providers. The ridesharing system in a specific implementation involves a computer-implemented capability for computational matching of potential participants in a ridesharing arrangement, wherein such system is adapted for prioritized ranking of target ridesharing attributes by such potential participants, involving allocation by potential participants of quantitative weight within a quantitative total budget of allocatable value to predetermined selection criteria, with such system having an input capability for inputting the allocations of potential participants, and the system being constructed and arranged for effecting the computational matching based on the allocations, with communication capability for outputting results of the computational matching to the potential participants.
Owner:VAN BUSKIRK PETER C
Methods related to immunostimulatory nucleic acid-induced interferon
InactiveUS6949520B1Increased proliferationIncrease productionPeptide/protein ingredientsGenetic material ingredientsSide effectMedicine
Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.
Owner:COLEY PHARMA GMBH +2
Methods and compositions involving mirna and mirna inhibitor molecules
InactiveUS20080050744A1Effective amountReduce percentageAntibacterial agentsOrganic active ingredientsBiologyCellular functions
The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and / or miRNA inhibitors are used in library screening assays.
Owner:ASURAGEN
Silk fibroin materials and use thereof
ActiveUS7842780B2Low densityIncreased proliferationPeptide/protein ingredientsMonocomponent fibroin artificial filamentPorosityBiology
The present invention provides processes for producing porous silk fibroin scaffold material. The porous silk fibroin scaffold can be used for tissue engineering. The porosity of the silk fibroin scaffolds described herein can be adjusted as to mimic the gradient of densities found in natural tissue. Accordingly, methods for engineering of 3-dimensional tissue, e.g. bone and cartilage, using the silk fibroin scaffold material are also provided.
Owner:TUFTS UNIV +1
Micrornas differentially expressed in pancreatic diseases and uses thereof
InactiveUS20090131348A1Reduce cell proliferationIncrease and decreasing cell proliferationOrganic active ingredientsAntipyreticDiseasePancreatic disease
The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as pancreatic disease, and using the profile in assessing the condition of a patient.
Owner:INTERPACE DIAGNOSTICS LLC
Compositions comprising nanostructures for cell, tissue and artificial organ growth, and methods for making and using same
ActiveUS20090220561A1Improve bone formationIncreased durabilityBioreactor/fermenter combinationsElectrolysis componentsIn vivoNanostructure
The invention provides articles of manufacture comprising biocompatible nanostructures comprising nanotubes and nanopores for, e.g., organ, tissue and / or cell growth, e.g., for bone, kidney or liver growth, and uses thereof, e.g., for in vitro testing, in vivo implants, including their use in making and using artificial organs, and related therapeutics. The invention provides lock-in nanostructures comprising a plurality of nanopores or nanotubes, wherein the nanopore or nanotube entrance has a smaller diameter or size than the rest (the interior) of the nanopore or nanotube. The invention also provides dual structured biomaterial comprising micro- or macro-pores and nanopores. The invention provides biomaterials having a surface comprising a plurality of enlarged diameter nanopores and / or nanotubes.
Owner:RGT UNIV OF CALIFORNIA
Radioactive intraluminal endovascular prosthesis and method for the treatment of aneurysms
A method for increasing the rate of thrombus formation and / or proliferative cell growth of a selected region (21) of cellular tissue (22) including the step of endovascularly irradiating the selected region (21) with radiation, having a dose range of endovascular radiation of about 1 Gy to about 600 Gy at a low dose rate of about 1 cGy / hr to about 320 cGy / hr, to increase thrombus formation and / or cell proliferation of the affected selected region (21). Preferably, the delivery means includes a deformable endovascular prosthesis (25) adapted for secured positioning adjacent to the selected region (21) of cellular tissue (22), and a radioactive source. This source cooperates with the deformable endovascular device (25) in a manner endovascularly irradiating the selected region with radiation, having the above-indicated dose range and low dose rate of endovascular radiation to increase thrombus formation and / or cell proliferation of the affected selected region (21).
Owner:ISOSTENT
Non-stochastic generation of genetic vaccines
InactiveUS6479258B1Improve abilitiesPotent and direct effect on proliferation and Ig-synthesisHydrolasesLibrary screeningAntigenMutagenic Process
This invention provides methods of obtaining vaccines by use of non-stochastic methods of directed evolution (DirectEvolution(TM)). These methods include non-stochastic polynucleotide site-satuaration mutagenesis (Gene Site Saturation Mutagenesis(TM)) and non-stochastic polynucleotide reassembly (GeneReassembly(TM)). Through use of the claimed methods, vectors can be obtained which exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.
Owner:VERENIUM CORPORATION
Tissue penetrating oral phototherapy applicator
InactiveUS20050107849A1Increase macrophage activityIncrease proliferationDental implantsCosmetic preparationsPigmentationsOral cavity
Oral phototherapy applicators are disclosed that are sized and shaped so as to fit at least partially in a user's mouth and have at least one radiation emitter coupled to an apparatus body to irradiate a portion of the oral cavity with phototherapeutic radiation, the emitter being capable of delivering radiation to a region of facial tissue. The apparatus can be configured to direct radiation to at least one portion of the oral cavity, e.g., a tooth, cheek, tongue, palate, throat, lymphatic tissue, blood, gland, follicle, collagen and pigmentation. In one embodiment, radiation from the emitter can penetrate the muscosal lining of the oral cavity and deliver phototherapeutic energy to a region of facial tissue. The apparatus can further include bristles to provide a phototherapeutic toothbrush. Alternatively, the apparatus body can be adapted for placement in a fixed position relative to the oral cavity during phototherapy.
Owner:PALOMAR MEDICAL TECH
Cartilage allograft plug
InactiveUS20050251268A1Increase chondrocyte migrationIncreased proliferationBone implantLigamentsInterference fitSubchondral bone
The invention is directed toward a cartilage repair assembly comprising a cylindrically shaped allograft structure of subchondral bone with an integral overlying smaller diameter cartilage cap which is treated to remove cellular debris and proteoglycans. The shaped structure is dimensioned to fit in a drilled bore in a cartilage defect area so that the subchondral bone of the structure engages the side wall of the bone portion of the drilled bore in an interference fit while the cartilage cap is spaced from cartilage portion of the side wall of the drilled bore forming a gap in which a milled cartilage and biocompatible carrier mixture is placed allowing cell transfer throughout the defect area. A method for inserting the shaped allograft structure into a cartilage defect area is also disclosed.
Owner:MUSCULOSKELETAL TRANSPLANT FOUND INC
Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
InactiveUS20050239134A1Increased proliferationPrevent proliferationPeptide/protein ingredientsAntiviralsDNA AptamersTgf β signalling
The present invention includes the selection and isolation of thioaptamers that target the signaling protein TGF-β1, compositions of such thioaptamers and the use of such thioaptamers to either block or enhance signal transduction of the TGF-β1 protein and thus function as, e.g., immunomodulatory agents. Thioaptamers may also be targeted alone or in combination with other thioaptamers against the ligand, the receptors, the ligand trap protein(s) and / or the co-receptors to modulate TGF-β signaling pathway.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Methods and compositions for delivering interleukin-1 receptor antagonist
ActiveUS20100055087A1Contribute to degenerationIncrease productionPeptide/protein ingredientsAntipyreticInterleukin 1 Receptor Antagonist ProteinPolyacrylamide
Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and / or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.
Owner:BIOMET MFG CORP
Isolation And Use Of Solid Tumor Stem Cells
InactiveUS20080178305A1Reduce spreadIncreased proliferationMaterial nanotechnologyMicrobiological testing/measurementAbnormal tissue growthMammary gland structure
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumor cells in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
Owner:ONCOMED PHARMA +1
Antibodies to human programmed death receptor pd-1
ActiveUS20100266617A1Increased activationIncreased proliferationSugar derivativesImmunoglobulins against animals/humansProgrammed deathAntibody
Antibodies which block the binding of human Programmed Death Receptor 1(hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.
Owner:MERCK SHARP & DOHME BV
Methods and compositions for delivering interleukin-1 receptor antagonist
ActiveUS20090220482A1Contribute to degenerationIncrease productionPeptide/protein ingredientsPharmaceutical delivery mechanismWhite blood cellPlatelet
Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.
Owner:BIOMET MFG CORP
Antibodies to human programmed death receptor pd-1
ActiveUS20130109843A1Increased activationIncreased proliferationImmunoglobulins against cell receptors/antigens/surface-determinantsDisease diagnosisProgrammed deathAntibody
Owner:MERCK SHARP & DOHME BV
Non-stochastic generation of genetic vaccines and enzymes
InactiveUS6713279B1Improve abilitiesPotent and direct effect on proliferation and Ig-synthesisAnimal cellsHydrolasesAntigenBiological property
This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by use of non-stochastic methods of directed evolution (DirectEvolution(TM)). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis(TM)) and non-stochastic polynucleotide reassembly (GeneReassembly(TM)). Through use of the claimed methods, genetic vaccines, enzymes, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. This invention provides methods of obtaining novel enzymes that have optimized physical & / or biological properties. Furthermore, this invention provides methods of obtaining a variety of novel biologically active molecules, in the fields of antibiotics, pharmacotherapeutics, and transgenic traits.
Owner:BP CORP NORTH AMERICA INC
Medical devices comprising porous layers for the release of therapeutic agents
InactiveUS20080051881A1Reduce retentionImprove cell adhesionSuture equipmentsStentsMedical deviceBiomedical engineering
In accordance with an aspect of the invention, implantable or insertable medical devices are provided in which a porous layer is disposed over a therapeutic-agent-containing region. In accordance with another aspect of the invention, medical devices are fabricated by a method in which a porous layer is deposited over a therapeutic-agent-containing region using a field-injection-based electrospray technique.
Owner:BOSTON SCI SCIMED INC
Methods related to immunostimulatory nucleic acid-induced interferon
InactiveUS20050169888A1Avoid side effectsIncreased proliferationPeptide/protein ingredientsGenetic material ingredientsSide effectMedicine
Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.
Owner:UNIV OF IOWA RES FOUND +2
Silk fibroin materials and use thereof
ActiveUS20100279112A1Low densityIncreased proliferationPeptide/protein ingredientsFilament/thread formingPorosityBiology
The present invention provides processes for producing porous silk fibroin scaffold material. The porous silk fibroin scaffold can be used for tissue engineering. The porosity of the silk fibroin scaffolds described herein can be adjusted as to mimic the gradient of densities found in natural tissue. Accordingly, methods for engineering of 3-dimensional tissue, e.g. bone and cartilage, using the silk fibroin scaffold material are also provided.
Owner:TRUSTEES OF TUFTS COLLEGE +1
Episomal reprogramming with chemicals
ActiveUS20110104125A1Easy to adaptHigh reprogramming efficiencyBiocideNervous disorderVector elementViral vector
Methods and composition of induction of pluripotent stem cells are disclosed. For example, in certain aspects methods for generating essentially vector-free induced pluripotent stem cells with cell signaling regulators are described. Furthermore, certain aspects of the invention provide novel compositions comprising induced pluripotent stem cells essentially free of exogenous retroviral vector elements in the presence of a medium comprising signaling inhibitors. In certain aspects, feeder-free episomal reprogramming methods may be provided.
Owner:FUJIFILM CELLULAR DYNAMICS INC
Light emitting toothbrush for oral phototherapy
InactiveUS7223270B2High activityIncreased proliferationCosmetic preparationsDental implantsBristleTooth Tissue
Oral phototherapy applicators are disclosed that are sized and shaped so as to fit at least partially in a user's mouth with a plurality of bristles of elongate shape coupled to an apparatus body. The Applicators can be adapted to brush the user's teeth and further include at least one radiation emitter coupled to the body to provide phototherapeutic radiation to a portion of the oral cavity other than tissue in contact with the bristles. In one embodiment, the phototherapy emitter irradiates both a region of tissue in contact with the bristles and a portion of the oral cavity that is not in contact with the apparatus. For example, the apparatus can include at least one emitter that irradiates tooth tissue in contact with the bristles and gum tissue surrounding the tooth tissue.
Owner:PALOMAR MEDICAL TECH
Pluripotent stem cell growing method
InactiveUS20070155013A1Proliferation potency can be increaseImprove gene transfer efficiencyArtificial cell constructsCell culture supports/coatingLiquid mediumCulture vessel
A novel growing method is provided for pluripotent stem cells such as ES cells. The method of the invention is a pluripotent stem cell growing method and gene transfer method in which pluripotent stem cells are cultured under conditions that maintain their undifferentiated state and pluripotency, the method being characterized by using a liquid medium and a culturing vessel having immobilized or coated on a substrate solid phase surface a molecule which is adhesive to the pluripotent stem cells in a fixed concentration, to grow the pluripotent stem cells in a dispersed state while maintaining their undifferentiated state and pluripotency, without using feeder cells, or to transfer and express a gene therein.
Owner:AKAIKE TOSHIHIRO
Methods, systems, and kits for plaque stabilization
InactiveUS20020032394A1Increasing the thicknessHigh strengthUltrasound therapyChiropractic devicesGrowth Factor GeneMedicine
Atherosclerotic plaque and blood vessels may be stabilized by directing vibrational energy, typically ultrasonic energy, into the adjacent blood vessel wall. Application of the vibrational energy, optionally in combination with growth factors, growth factor genes, or other substances which enhance growth instability of a fibrotic cap over the plaque, will reduce the risk of rupture of unstable plaque and inhibit the conversion of stable plaque into unstable plaque.
Owner:PHARMASONICS
Nanofiber construct and method of preparing thereof
InactiveUS20060154063A1Improve hydrophilicityGood bone conductionPharmaceutical delivery mechanismElectro-spinningFiberComposite nanofibers
The present invention provides a composite nanofiber construct comprising: at least a first nanofiber comprising at least a polymer and at least a calcium salt nanoparticle, wherein the ratio of polymer to calcium salt nanoparticle is between the range of 99:1 and 10:90 weight percent; and at least a second nanofiber comprising at least a polymer and at least a calcium salt nanoparticle, wherein the ratio of polymer to calcium salt nanoparticle is between the range of 100:0 and 70:30 weight percent. The present invention also provides a method of preparing the composite nanofiber construct.
Owner:NAT UNIV OF SINGAPORE
Non Proliferating Thorium Nuclear Fuel Inert Metal Matrix Alloys for Fast Spectrum and Thermal Spectrum Thorium Converter Reactors
InactiveUS20080144762A1Improve heat transfer performanceRobust assemblyOptical rangefindersNuclear energy generationHigh energyEpithermal neutron
A set of alloy formulations is disclosed to use with thorium based nuclear fuels in a fast spectrum reactor; with thorium based nuclear fuels in existing thermal spectrum power reactors; for medical isotope production in the epithermal, the fast, the fission spectrum and the thermal spectra; and to use as fuel in test and experimental reactors that are non proliferative. The alloys form inert metal matrixes to hold fine particles of dispersed thorium containing fuel. The formulations also are useful for the production of medical and commercial isotopes in the high energy, fast and epithermal neutron spectra.
Owner:RGT UNIV OF CALIFORNIA
Nucleic acids encoding JTT-1 protein
InactiveUS7045615B2Increased proliferationImprove purification effectBacteriaPeptide/protein ingredientsCell adhesionAutoimmune responses
Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
Owner:JAPAN TOBACCO INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com